Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
暂无分享,去创建一个
Philippe Dessen | Stefan Michiels | Lajos Pusztai | Fabrice Andre | Gilles Vassal | G. Hortobagyi | L. Pusztai | S. Michiels | F. André | W. Symmans | B. Job | P. Dessen | C. Richon | V. Lazar | G. Vassal | C. Liedtke | A. Tordai | S. Delaloge | Vladimir Lazar | Bastien Job | Gabriel N. Hortobagyi | Bailang Wang | Cornelia Liedtke | Attila Tordai | Kai Yan | Suzette Delaloge | Catherine Richon | Bailang Wang | W. Fraser Symmans | Kai Yan
[1] G. Hortobagyi,et al. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers , 2008 .
[2] Lajos Pusztai,et al. Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer , 2007, Clinical Cancer Research.
[3] J. Fridlyand,et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. , 2007, Cancer research.
[4] Judith Abrams,et al. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. , 2006, Cancer research.
[5] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[6] Alan Mackay,et al. FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.
[7] Robert Tibshirani,et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.
[8] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Christian J Stoeckert,et al. STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. , 2006, Genome research.
[10] Jeroen Beliën,et al. ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data , 2006, Bioinform..
[11] P. Nederlof,et al. Array-CGH and breast cancer , 2006, Breast Cancer Research.
[12] Ajay N. Jain,et al. Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.
[13] C. Rouveirol,et al. Computation of recurrent minimal genomic alterations from array-CGH data , 2006, Bioinform..
[14] Meritxell Bellet,et al. The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. , 2006, Cancer genetics and cytogenetics.
[15] B. Ylstra,et al. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH) , 2006, Nucleic acids research.
[16] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[17] Zohar Yakhini,et al. Joint Analysis of DNA Copy Numbers and Gene Expression Levels , 2004, WABI.
[18] David E. Gloriam,et al. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. , 2004, Genomics.
[19] D. Ginsberg. E2F3-a novel repressor of the ARF/p53 pathway. , 2004, Developmental cell.
[20] G. Meijer,et al. Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma , 2004, Modern Pathology.
[21] Pablo Tamayo,et al. Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Saydam,et al. DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. , 2003, Cancer genetics and cytogenetics.
[23] J. Stec,et al. Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma , 2003, Cancer.
[24] Christian A. Rees,et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] G. Prendergast,et al. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[26] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[27] S. Nass,et al. Defining a role for c-Myc in breast tumorigenesis , 1997, Breast Cancer Research and Treatment.
[28] Y. Benjamini,et al. More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.
[29] Y. Sekido,et al. Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .
[30] Bongsoo Park,et al. BMC Genomics , 2007 .
[31] J. Fridlyand,et al. Deletion of Chromosome 11 q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer , 2007 .
[32] Ian M. Wilson,et al. Array CGH technologies and their applications to cancer genomes , 2005, Chromosome Research.
[33] B. Dörken,et al. Apoptosis: implications of basic research for clinical oncology. , 2001, The Lancet. Oncology.
[34] P. Sneath,et al. Numerical Taxonomy , 1962, Nature.